A Phase I/II Open Label, Dose Escalation Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Trial Profile

A Phase I/II Open Label, Dose Escalation Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Palifermin (Primary) ; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Filgrastim; Fludarabine; Furosemide; Mesna; Methotrexate; Prednisone; Rituximab; Sirolimus; Tacrolimus; Vincristine
  • Indications Graft-versus-host disease
  • Focus Adverse reactions
  • Most Recent Events

    • 03 Nov 2017 Planned End Date changed from 1 Jan 2019 to 1 Jan 2023.
    • 03 Nov 2017 Planned primary completion date changed from 1 Jan 2019 to 1 Jan 2023.
    • 04 May 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top